The Centers for Medicare and Medicaid Services should reverse its proposal to base the selection of drugs eligible for Medicare price negotiation in Part D on gross spending before rebates rather than on net costs, two large Part D plan sponsors with major pharmacy benefit manager subsidiaries argue in recent comments to the agency.
CMS included the policy in its proposed rule on Medicare Advantage and Part D policy and technical changes for 2024...







